MedTrace Logo

Ipilimumab and Imatinib Mesylate in Advanced Cancer

NCT01738139 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2024-03-21

No results posted yet for this study

Summary

This phase I trial studies the side effects and best dose of ipilimumab and imatinib mesylate in treating patients with solid tumors that have spread to other places in the body or cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving ipilimumab and imatinib mesylate may work better in treating patients with solid tumors.

Conditions

  • Advanced Malignant Solid Neoplasm
  • C-KIT Tyrosine Kinase Protein Overexpression
  • Clinical Stage IV Cutaneous Melanoma AJCC v8
  • Metastatic Gastrointestinal Stromal Tumor
  • Metastatic Malignant Solid Neoplasm
  • Metastatic Melanoma
  • Pathologic Stage IV Cutaneous Melanoma AJCC v8
  • Unresectable Melanoma
  • Unresectable Solid Neoplasm

Interventions

DRUG

Imatinib Mesylate

Given PO

BIOLOGICAL

Ipilimumab

Given IV

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • David S Hong · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-19
Primary Completion
2022-12-13
Completion
2023-12-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01738139 on ClinicalTrials.gov